Filing Details

Accession Number:
0000899243-21-042710
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2021-11-03 16:20:18
Reporting Period:
2021-10-26
Accepted Time:
2021-11-03 16:20:18
Original Submission Date:
2021-10-28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1840233 Xilio Therapeutics Inc. XLO () X0
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1780602 Sv7 Impact Medicine Fund Lp 71 Kingsway
London X0 WC2B 6ST
No No Yes No
1889859 Llp Gp (Imf) Sv7 71 Kingsway
London X0 WC2B 6ST
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-10-26 998,544 $0.00 998,544 No 4 C Direct
Common Stock Acquisiton 2021-10-26 998,544 $0.00 998,544 No 4 C Indirect See footnote
Common Stock Acquisiton 2021-10-26 302,588 $0.00 1,301,132 No 4 C Direct
Common Stock Acquisiton 2021-10-26 302,588 $0.00 1,301,132 No 4 C Indirect See footnote
Common Stock Acquisiton 2021-10-26 312,500 $16.00 1,613,632 No 4 P Direct
Common Stock Acquisiton 2021-10-26 312,500 $16.00 1,613,632 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Indirect See footnote
No 4 C Direct
No 4 C Indirect See footnote
No 4 P Direct
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Convertible Preferred Stock Disposition 2021-10-26 9,486,166 $0.00 998,544 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2021-10-26 9,486,166 $0.00 998,544 $0.00
Common Stock Series C Convertible Preferred Stock Disposition 2021-10-26 2,874,595 $0.00 302,588 $0.00
Common Stock Series C Convertible Preferred Stock Disposition 2021-10-26 2,874,595 $0.00 302,588 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Indirect
0 No 4 C Direct
0 No 4 C Indirect
Footnotes
  1. The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date.
  2. Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021.
  3. Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom.
  4. This Form 4 has been amended to include 312,500 shares of Common Stock purchased by SV7 Impact Medicine Fund LP in connection with Xilio's initial public offering.